Globus Medical Inc (NYSE:GMED) has been given an average recommendation of “Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $54.55.
GMED has been the subject of several research analyst reports. Morgan Stanley raised their price objective on shares of Globus Medical from $53.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, May 3rd. Needham & Company LLC raised their price objective on shares of Globus Medical from $57.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, May 3rd. Zacks Investment Research upgraded shares of Globus Medical from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a report on Tuesday, April 24th. Oppenheimer set a $52.00 price objective on shares of Globus Medical and gave the stock a “hold” rating in a report on Thursday, May 3rd. Finally, BTIG Research restated a “neutral” rating and issued a $37.00 price objective on shares of Globus Medical in a report on Monday, April 16th.
In other news, VP Eric Schwartz sold 10,000 shares of Globus Medical stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $53.79, for a total transaction of $537,900.00. Following the completion of the transaction, the vice president now directly owns 10,000 shares in the company, valued at $537,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David C. Paul sold 6,841 shares of Globus Medical stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $52.95, for a total transaction of $362,230.95. Following the transaction, the insider now owns 605,871 shares of the company’s stock, valued at $32,080,869.45. The disclosure for this sale can be found here. Insiders sold 159,279 shares of company stock valued at $8,889,746 over the last 90 days. 28.44% of the stock is currently owned by company insiders.
Shares of Globus Medical traded down $0.06, reaching $52.35, during trading on Tuesday, Marketbeat reports. 748,681 shares of the stock were exchanged, compared to its average volume of 519,690. The firm has a market cap of $5.15 billion, a P/E ratio of 39.96, a P/E/G ratio of 2.68 and a beta of 0.57. Globus Medical has a 1 year low of $27.79 and a 1 year high of $57.55.
Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Wednesday, August 1st. The medical device company reported $0.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.09. Globus Medical had a net margin of 19.91% and a return on equity of 15.14%. The business had revenue of $173.40 million during the quarter, compared to analyst estimates of $168.03 million. During the same period last year, the business posted $0.32 earnings per share. Globus Medical’s quarterly revenue was up 13.8% compared to the same quarter last year. sell-side analysts anticipate that Globus Medical will post 1.55 earnings per share for the current year.
About Globus Medical
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum.
See Also: Earnings Per Share (EPS) Explained
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.